Hybio Pharmaceutical Co., Ltd. — Investor Relations & Filings

Hybio Pharmaceutical Co., Ltd. specializes in the research, development, and manufacturing of peptide-based medicines. The company operates a vertically integrated platform covering the entire peptide value chain, from raw materials and active pharmaceutical ingredients (APIs) to finished dosage forms. Its product portfolio primarily targets metabolic disorders, cardiovascular diseases, and digestive health. Key offerings include GLP-1 receptor agonists such as Liraglutide and Semaglutide, alongside treatments like Teriparatide and Atosiban. Hybio maintains advanced production facilities compliant with international quality standards, enabling the supply of high-purity peptide products to global markets. The firm focuses on technological innovation in peptide synthesis and long-acting drug delivery systems to address unmet medical needs in chronic disease management.